Healthcare Dealmakers Optimistic for More Deals

Healthcare dealmakers are anticipating more deals following a wave of biotech company takeovers, with the JPMorgan Healthcare Conference in San Francisco set to attract over 8,000 attendees. Last month, drugmakers announced roughly $25 billion worth of U.S.-listed biotech deals, reflecting a 8% growth in global healthcare M&A activity in 2023. The conference will cover topics such as weight-loss drugs, regulation, antitrust, financing environment, and potential effects of the 2024 U.S. presidential election on the industry.